Advanced search
Publication Cover
Journal of Medical Economics Volume 21, 2018 - Issue 2
Submit an article Journal homepage
2,937
Views
12
CrossRef citations to date
0
Altmetric
Rheumatology

Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective

Ron GoereeGoeree Consulting Ltd, Hamilton, Ontario, Canada; ;McMaster University, Hamilton, Ontario, Canada; Correspondence[email protected]
,
Sima Chiva-RazaviNovartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada;
,
Praveen GundaNovartis Product Life Cycle Services-NBS, Novartis Healthcare Private Limited, Hyderabad, India;
,
Christopher N. GrahamRTI Health Solutions, Research Triangle Park, NC, USA;
,
LaStella MilesRTI Health Solutions, Research Triangle Park, NC, USA;
,
Efthalia NikoglouNovartis Product Lifecycle Services – NBS, Novartis Global Service Center, Dublin, Ireland;
,
Steffen M. JuglNovartis Pharma AG, Basel, Switzerland;
&
Dafna D. GladmanToronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
 show all
Pages 163-173 | Received 09 Aug 2017, Accepted 13 Sep 2017, Published online: 19 Oct 2017

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Sebastian Himmler, Malina Mueller, Bintu Sherif & Dennis Ostwald. (2020) A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Review of Pharmacoeconomics & Outcomes Research 20:4, pages 369-378.
Read now
Atsuyuki Igarashi, Ataru Igarashi, Christopher N. Graham, Isabelle Gilloteau & Yumiko Tani. (2019) Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. Journal of Medical Economics 22:1, pages 7-15.
Read now
Giorgio L Colombo, Sergio Di Matteo, Chiara Martinotti, Steffen M Jugl, Praveen Gunda, Mariantonietta Naclerio & Giacomo M Bruno. (2018) Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. ClinicoEconomics and Outcomes Research 10, pages 477-491.
Read now

Articles from other publishers (9)

Paolo Gisondi, Davide Geat, Martina Maurelli, Luca Degli Esposti, Francesco Bellinato & Giampiero Girolomoni. (2022) Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease. Vaccines 10:5, pages 646.
Crossref
Maria de Fátima P. Oliveira, Bruno de O. Rocha & Gleison V. Duarte. (2021) PASI 100 response to secukinumab in primary failure to ustekinumab: analysis of cost‐effectiveness among biological drugs. International Journal of Dermatology 60:9, pages 1165-1167.
Crossref
Nicolas Iragorri, Glen Hazlewood, Braden Manns, Laura Bojke & Eldon Spackman. (2021) Model to Determine the Cost‐Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis. Arthritis Care & Research 73:2, pages 266-274.
Crossref
Bruna de Oliveira Ascef, Ana Carolina de Freitas Lopes & Patrícia Coelho de Soárez. (2020) Health technology assessment of biosimilars worldwide: a scoping review. Health Research Policy and Systems 18:1.
Crossref
Bernd Schweikert, Chiara Malmberg, Örjan Åkerborg, Gayathri Kumar, Debby Nott, Sandeep Kiri, Christophe Sapin & Susanne Hartz. (2020) Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. PharmacoEconomics - Open 4:4, pages 635-648.
Crossref
Afschin Gandjour & Dennis A. Ostwald. (2019) Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. Applied Health Economics and Health Policy 18:1, pages 109-125.
Crossref
Timo Purmonen, Kari Puolakka, Devarshi Bhattacharyya, Minal Jain & Janne Martikainen. (2018) Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Vanessa Buchanan, Will Sullivan, Chris Graham, LaStella Miles, Steffen Marc Jugl, Praveen Gunda, Anna Halliday & Bruce Kirkham. (2018) Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK. PharmacoEconomics 36:7, pages 867-878.
Crossref
Lucia Sara D’Angiolella, Paolo Angelo Cortesi, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giancarlo Cesana & Lorenzo Giovanni Mantovani. (2018) Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. PharmacoEconomics 36:5, pages 567-589.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.